Rosuvastatin treatment protects against nitrate-induced oxidative stress

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 2, 2005, Pages 177-184

  Otto, Anne ^a   Fontaine, David ^a   Fontaine, Jeanine ^a   Berkenboom, Guy ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

NAD(P)H oxidase; NTG tolerance; Oxidative stress; Statins

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCERYL TRINITRATE; LUCIGENIN; LUMINOL; NITRATE; OXYGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROSUVASTATIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CHEMOLUMINESCENCE; CLINICAL PATHWAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; LONG TERM CARE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RAT STRAIN; THORACIC AORTA; UPREGULATION; WESTERN BLOTTING;

ACETYLCHOLINE; ANIMALS; AORTA, ABDOMINAL; AORTA, THORACIC; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NITROGLYCERIN; OXIDATIVE STRESS; PHENYLEPHRINE; PYRIMIDINES; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SULFONAMIDES; VASODILATION;

EID: 23044445561     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000167010.98177.78     Document Type: Article

References (40)

1. Packard CJ. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary prevention Study (WOSCOPS). Circulation. 1998;97:1440-1445.
2. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129-1135.
3. Feron O, Dessy C, Desager J-P, et al. hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation. 2001;103:113-118.
4. Laufs U, Gertz K, Dirnagl U, et al. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res. 2002;942:23-30.
5. Rikitake Y, Kawashima S, Takeshita S, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 2001;154: 87-96.
6. Wagner AH, Köhler T, Rückschloss U, et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol. 2000;20:61-69.
7. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844.
8. Münzel T, Sayegh H, Freeman BA, et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest. 1995;95:187-194.
9. Münzel T, Kurz S, Rajagopalan S, et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest. 1996;98:1465-1470.
10. Münzel T, Li H, Mollnau H, et al. Effects of long-term nitroglycerin treatment on endothelial nitric oxidee synthase (NOSIII) gene expression, NOSIII-mediated superoxide production, and vascular NO bioavailability. Circ Res. 2000;86:e7-e12.
11. Gori T, Mak SS, Kelly S, et al. Evidence supporting abnormalities in nitric oxide synthase function induced by nitroglycerin in humans. J Am Coll Cardiol. 2001;38:1096-1101.
12. Ogonowski AA, Kaesemeyer WH, Jin L, et al. Effects of NO donors and synthase agonists on endothelial cell uptake of L-Arginine and superoxide production. Am J Physiol Cell Physiol. 2000;278:C136-C143.
13. Fontaine D, Otto A, Fontaine J, et al. Prevention of nitrate tolerance by long-term treatment with statins. Cardiovasc Drugs Ther. 2003;17:123-128.
14. Rader DJ, Davidson MH, Caplan RJ, et al. Lipid and apoliporotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Am J Cardiol. 2003; 91(Suppl):20C-24C.
15. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol. 2002;42:963-970.
16. Shepherd J, Hunninghake DB, Barter P, et al. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol. 2003;91:11C-17C.
17. Cilla DD Jr, Whitfield LR, Gibson DM, et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther. 1996;60:687-695.
18. Dostal LA, Whitfield LR, Anderson JA. Fertility and general reproduction studies in rats with the HMG-CoA reductase inhibitor, atorvastatin. Fundam Appl Toxicol. 1996;32:285-292.
19. Beswick RA, Dorrance AM, Leite R, et al. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension. 2001;38:1107-1111.
20. Berkenboom G, Langer I, Carpentier Y, et al. Ramipril prevents endothelial dysfunction induced by oxidized low-density lipoproteins: a bradykinin-dependent mechanism. Hypertension. 1997;30:371-376.
21. Levy JV. Prostacyclin-induced contraction of isolated aortic strips from normal and spontaneously hypertensive rats (SHR). Prostaglandins. 1980;19:517-525.
22. Daiber A, August M, Baldus S, et al. Measurement of NAD(P)H oxidase-derived superoxide with the luminol analogue L-012. Free Radic Biol Med. 2004;36:101-111.
23. Fontaine D, Fontaine J, Dupont I, et al. Chronic hydroxymethylglutaryl coenzyme a reductase inhibition and endothelial function of the normocholesterolemic rat: comparison with angiotensin-converting enzyme inhibition. J Cardiovasc Pharmacol. 2002;40:172-180.
24. Li Y, Zhu H, Kuppusamy P, et al. Validation of lucigenin (bis-N-methylacridium) as a chemilumigenic probe for detecting superoxide anion radical production by enzymatic and cellular systems. J Biol Chem. 1998;273:2015-2023.
25. Berkenboom G, Brekine D, Unger P, et al. Chronic angiotensin-converting enzyme inhibition and endothelial function of rat aorta. Hypertension. 1995;26:738-743.
26. Meyer JW, Schmitt ME. A central role for the endothelial NADPH oxidase in atherosclerosis. FEBS Lett. 2000;472:1-4.
27. Wassmann S, Laufs U, Baumer AT, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001;59:646-654.
28. Haendeler J, Hoffmann J, Zeiher AM, et al. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation. 2004;110:856-861.
29. Münzel T, Heitzer T, Brockhoff C. Neurohormonal activation and nitrate tolerance: implications for concomitant therapy with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Am J Cardiol. 1998;81: 30A-40A.
30. Parker JD. Nitrate tolerance, oxidative stress, and mitochondrial function: another worrisome chapter on the effects of organic nitrates. J Clin Invest. 2004;113:352-354.
31. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USA. 2002;99:8306-8311.
32. Sydow K, Daiber A, Oelze M, et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest. 2004;113:482-489.
33. Fung HL. Biochemical mechanism of nitroglycerin action and tolerance: is this old mystery solved? Annu Rev Pharmacol Toxicol. 2004;44:67-85.
34. Li JM, Shah AM. Differential NADPH- versus NADH-dependent superoxide production by phagocyte-type endothelial cell NADPH oxidase. Cardiovasc Res. 2001;52:477-486.
35. Bayraktutan U, Draper N, Lang D, et al. Expression of functional neutrophil-type NADPH oxidase in cultured rat coronary microvascular endothelial cells. Cardiovasc Res. 1998;38:256-262.
36. Griendling KK, Minieri CA, Ollerenshaw JD, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.
37. Guzik TJ, West NE, Black E, et al. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation. 2000;102:1744-1747.
38. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003;111:1201-1209.
39. Nazzaro P, Manzari M, Merlo M, et al. Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension. 1999;33:719-725.
40. Esper RJ, Machado R, Vilarino J, et al. Endothelium-dependent responses in patients with hypercholesterolemic coronary artery disease under the effects of simvastatin and enalapril, either separately or combined. Am Heart J. 2000;140:684-689.